Sign in
Taking people in United StatesPhase 1/2

Tests a CAR-T cell therapy in children with relapsed blood cancers

Tests modified T cells in children with B-cell leukemia or lymphoma that returned.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Registry title
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Status
Recruiting
Phase
Phase 1/2
People taking part
45 people, planned
Started
10 Mar 2021
Expected to end
10 Mar 2031
Type of study
Interventional, 2 groups
Treatments tested
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that came back or did not respond to treatment, and whose cancer cells carry CD19.

Age
31 days to 30 years
Sex
Males and females can join.
Disease stage
B-cell ALL or B-cell non-Hodgkin lymphoma. Cohort One: relapsed two or more times, relapsed after a bone marrow transplant, or did not respond to standard therapy. Cohort Two: B-ALL in first relapse with certain high-risk features.
Earlier treatment
Cohort Two: cannot or chose not to receive commercially available CD19 CAR-T therapy. Must meet the clinical criteria for leukapheresis, or have a leukapheresis product already collected and stored.
Biomarker or test result
CD19 on the cancer cells, confirmed by flow cytometry, immunohistochemistry, or both.

Main reasons for not taking part

  • Rapidly worsening disease without adequate bridging treatment
  • Active graft-versus-host disease
  • Active, uncontrolled, life-threatening infection
  • Severe heart, lung, liver or kidney problems
  • Pregnant, or known HIV, active hepatitis B or active hepatitis C infection

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Meets clinical criteria for leukapheresis or has a leukapheresis product previously collected and stored per recommended guidelines
  • Provision of signed and dated consent form from parent or guardian (patients <18), the patient themselves (>18), or legally authorized representative (patient >18 who lack decision-making capacity); Pediatric patients will be included in age-appropriate discussions and assent will be obtained for those > 7 years of age, when appropriate, according to institutional standards
  • Willingness to participate in long term follow up study
  • Stated willingness to comply with all study procedures and be available for the duration of the study
  • Males OR non-pregnant, non-breastfeeding females; o Patients of child-bearing potential or capable of fathering a child must agree to use highly effective contraception from the time of initial CAR T cell administration though 12 months following the final administration of investigational product
  • Aged 31 days to 30 years (inclusive) at time of consent and enrollment
  • Acute Lymphoblastic Leukemia (ALL) OR Non-Hodgkin Lymphoma (NHL) of B-cell origin that:; Has confirmed expression of CD19 by flow cytometry, immunohistochemistry (IHC), or both; Cohort One Criteria:
  • Meets any one of the following conditions:; Relapsed two or more times; Relapsed at any time after allogeneic BMT; Refractory to standard therapy as determined by the treating physician; Meets criteria for BMT but is ineligible as determined by the treating physician Patient and/or parents declining BMT options and would prefer CAR-T Therapy
  • Non-Hodgkin Lymphoma includes all of the following:; Diffuse large B-cell lymphoma (DLBCL); Burkitt Lymphoma; Intermediate lymphoma between Burkitt and DLBCL; Primary Mediastinal B-cell Lymphoma (PMBL); Follicular lymphoma; High grade B cell lymphoma; Transformed lymphoma; Cohort Two Criteria:
  • B-ALL in first relapse with any one of the following conditions:; High-risk genomic alterations at initial diagnosis such as KMT2A gene rearrangement, t(17;19), hypodiploidy, Ph-like mutations, BCR-ABL1 fusion (Ph+ ALL), iAMP21, and TP53 inactivating mutation/deletion; Isolated CNS relapse such that cranial radiation would be indicated as a component of standard salvage therapy; Down syndrome; Minimal residual disease (MRD) positivity of > 0.01% by FACS or > 0 clonal sequences by NGS in bone marrow post re-induction chemotherapy; Age 18 years or older. OR Newly diagnosed with persistent MRD ≥ 0.01% by flow cytometry in bone marrow at end of consolidation
  • Performance score (Lansky or Karnofsky) of 50% or better
  • Unable to or declined to receive commercially available CD19 CAR-T Therapy

Who cannot take part

  • Evidence of rapidly progressive disease without adequate salvage/bridging regimens as determined by the investigator
  • Active Graft-versus-Host Disease (GvHD)
  • Active, uncontrolled, life-threatening infection that at the determination of the treating physician would preclude safe leukapheresis or tolerance of LD chemotherapy, cell infusion, or cytokine release syndrome
  • Known HIV infection, or active Hepatitis B or active Hepatitis C infection
  • Evidence of severe organ dysfunction as defined by:; Myocardial dysfunction: Ejection fraction ≤ 40% or shortening fraction ≤ 28%, evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and clinically significant electrocardiogram (ECG) findings; Baseline oxygen saturation of ≤ 90% on room air; Transaminases > 10x upper limit of normal (ULN) or bilirubin >2x the ULN, unless thought to be related to primary disease; Estimated Cr clearance <60 mL/min/1.73 m2 (if nuclear medicine GFR or other more specific testing exceeds this level than it can supersede the estimated clearance)
  • Post-pubertal females that are pregnant, planning to become pregnant, or unwilling to use birth control (includes abstinence) for the study duration

Where in United States

  • Children's Hospital ColoradoAurora, United StatesContact: Vanessa Fabrizio, MD, MSTaking people

About the trial

What the trial wants to find out

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.

The 2 groups in the trial

  • Phase I: Dose EscalationTreatment being tested

    First 4-18 subjects enrolled. Treated with escalating doses of therapy until the recommended phase 2 dose (RP2D) is determined.

    Treatment: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

  • Phase II: Dose ExpansionTreatment being tested

    Up to 18 additional subjects will be treated at the recommended Phase 2 dose (RP2D) to allow for 12 total subjects to be treated in each cohort, including those treated within the phase 1 portion at the RP2D.

    Treatment: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase I/II Dose Escalation and Preliminary Efficacy of CD19 Directed CAR-T Cells Generated Using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL)
Plain-language title
Tests a CAR-T cell therapy in children with relapsed blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 September 2026